dc.contributor.author | Walsh, JS | |
dc.contributor.author | Marshall, H | |
dc.contributor.author | Smith, IL | |
dc.contributor.author | Greenfield, DM | |
dc.contributor.author | Swain, J | |
dc.contributor.author | Best, E | |
dc.contributor.author | Ashton, J | |
dc.contributor.author | Brown, JM | |
dc.contributor.author | Huddart, R | |
dc.contributor.author | Coleman, RE | |
dc.contributor.author | Snowden, JA | |
dc.contributor.author | Ross, RJ | |
dc.date.accessioned | 2020-01-06T11:40:25Z | |
dc.date.issued | 2019-11-12 | |
dc.identifier.citation | PLoS medicine, 2019, 16 (11), pp. e1002960 - ? | |
dc.identifier.issn | 1549-1676 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3479 | |
dc.identifier.eissn | 1549-1676 | |
dc.identifier.doi | 10.1371/journal.pmed.1002960 | |
dc.description.abstract | BACKGROUND: Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and radiotherapy. We have undertaken a double-blind, placebo-controlled, 6-month trial of testosterone replacement in young male cancer survivors with borderline low testosterone (7-12 nmol/l). METHODS AND FINDINGS: This was a multicentre United Kingdom study conducted in secondary care hospital outpatients. Male survivors of testicular cancer, lymphoma, and leukaemia aged 25-50 years with morning total serum testosterone 7-12 nmol/l were recruited. A total of 136 men were randomised between July 2012 and February 2015 (42.6% aged 25-37 years, 57.4% 38-50 years, 88% testicular cancer, 10% lymphoma, matched for body mass index [BMI]). Participants were randomised 1:1 to receive testosterone (Tostran 2% gel) or placebo for 26 weeks. A dose titration was performed after 2 weeks. The coprimary end points were trunk fat mass and SF36 Physical Functioning score (SF36-PF) at 26 weeks by intention to treat. At 26 weeks, testosterone treatment compared with placebo was associated with decreased trunk fat mass (-0.9 kg, 95% CI -1.6 to -0.3, p = 0.0073), decreased whole-body fat mass (-1.8 kg, 95% CI -2.9 to -0.7, p = 0.0016), and increased lean body mass (1.5 kg, 95% CI 0.9-2.1, p < 0.001). Decrease in fat mass was greatest in those with a high truncal fat mass at baseline. There was no treatment effect on SF36-PF or any other QoL scores. Testosterone treatment was well tolerated. The limitations of our study were as follows: a relatively short duration of treatment, only three cancer groups included, and no hard end point data such as cardiovascular events. CONCLUSIONS: In young male cancer survivors with low-normal morning total serum testosterone, replacement with testosterone is associated with an improvement in body composition. TRIAL REGISTRATION: ISRCTN: 70274195, EudraCT: 2011-000677-31. | |
dc.format | Electronic-eCollection | |
dc.format.extent | e1002960 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | PUBLIC LIBRARY SCIENCE | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Adipose Tissue | |
dc.subject | Humans | |
dc.subject | Leukemia | |
dc.subject | Lymphoma | |
dc.subject | Testicular Neoplasms | |
dc.subject | Testosterone | |
dc.subject | Double-Blind Method | |
dc.subject | Placebo Effect | |
dc.subject | Body Composition | |
dc.subject | Quality of Life | |
dc.subject | Adult | |
dc.subject | Middle Aged | |
dc.subject | Male | |
dc.subject | United Kingdom | |
dc.subject | Cancer Survivors | |
dc.title | Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-10-11 | |
rioxxterms.versionofrecord | 10.1371/journal.pmed.1002960 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-11-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | PLoS medicine | |
pubs.issue | 11 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.publication-status | Published | |
pubs.volume | 16 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
dc.contributor.icrauthor | Huddart, Robert | |